Company News
Connect with us at BIO International Convention Digital Event 2021!
Kelun-Biotech Will Present an Update on SKB264 at 2021 ESMO
Kelun-Biotech will present an oral update on SKB264 at 2021 ESMO Annual Meeting held from September 16-21.
September 10, 2021
KLUS Pharma is Attending 2021 BioPharm America Digital Conference
KLUS Pharma will attend 2021 BioPharm America Digital Conference held from September 20-23.
September 10, 2021
Kelun-Biotech Will Present Updates for A166 at ASCO
Kelun-Biotech will attend and present at ASCO 2021 for A166, an anti-HER2 ADC.
May 20, 2021
KLUS Pharma is Attending BIO International Convention Digital Event
KLUS Pharma will attend BIO International Convention Digital 2021 from June 14-18.
May 20, 2021
Kelun-Biotech and Ellipses Pharma Announce a Licensing Agreement for A400
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics
March 26, 2021
KLUS Pharma is Attending BIO-Europe Spring
KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.
March 5, 2021
KLUS Pharma is Attending BIO Partnering at JPM
KLUS Pharma will attend BIO Partnering at JPM Digital Event held on January 11-15, 2021.
December 5, 2020
IND for KL-A289 is Approved in China
The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.
September 2, 2020
Looking for Partnerships to Combat COVID-19
We are looking for partnerships to develop and distribute ACV200-17, a peptide drug to prevent COVID-19, in affected countries.
June 1, 2020
KLUS Pharma to Present at BIO Digital
KLUS Pharma will present an update for SKB264, a novel TROP2 ADC, at BIO Digital Event held on June 8-12, 2020.
May 7, 2020
KLUS Pharma to Present at ASCO Annual Meeting
KLUS Pharma will present clinical update for our HER2 and TROP2 ADC programs at ASCO held on May 29-31, 2020.
April 25, 2020